FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311698903> ?p ?o ?g. }

• W4311698903 abstract "<h3>Introduction</h3> There are no real-world studies looking at tolerability of Nintedanib in patients who have a diagnosis of progressive fibrosing interstitial lung disease (PFILD) being treated with Nintedanib alongside immune suppressant and/or Prednisolone, comparing this to tolerability in idiopathic pulmonary fibrosis (IPF) patients. These patients were excluded from the INBUILD trial¹. <h3>Hypothesis</h3> Nintedanib will be less well tolerated in PFILD, compared to IPF due to immunosuppression/corticosteroid co-prescription. <h3>Methods</h3> Retrospective study of patients treated with Nintedanib on a Named Individual Patient Supply (NIPS) by Boehringer UK for PFILD at a tertiary referral ILD specialist centre with treatment started between November 2019-January 2021. A cohort of IPF patients from our centre was used for comparison. All data was collected using hospital medical records. Tolerability and concurrent treatment data were collected from initial prescription to June 2022 for the PFILD cohort (maximum follow-up 30 months). Data for the IPF patients was collected from initial prescription until November 2017 (maximum follow-up 31 months). <h3>Results</h3> Data from 47 PFILD patients and 51 IPF patients were compared (table 1). In the PFILD cohort, 42 (89.4%) were taking Prednisolone at initiation of Nintedanib, and 26 (55.3%) were taking immunosuppression, with the most common being Mycophenolate (80.8% of patients on immunosuppressive therapy). During the follow-up, immunosuppressant doses were not required to be changed due to side effects other than infections, and 1 case of raised liver function tests. There was no statistical difference between either discontinuation rates for Nintedanib, tolerability (need to reduce the dosage), or side effect profile between both cohorts. <h3>Conclusions</h3> This real-world study demonstrated that concurrent immunosuppression therapy did not affect the tolerability of Nintedanib in PFILD patients, therefore concerns over additive side effects may be unfounded. Useful further questions would be to assess whether there is a gender or age contribution to tolerability, whether a larger cohort would show differential hepatotoxicity, and whether the use of different immunosuppressants would have affected tolerability (the majority in this cohort took Mycophenolate). <h3>Reference</h3> Flaherty KR, Wells AU, Cottin V, <i>et al</i>. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. <i>N Engl J Med</i> 2019; <b>381</b>(18):1718–1727." @default.
• W4311698903 created "2022-12-28" @default.
• W4311698903 creator A5001206463 @default.
• W4311698903 creator A5008951890 @default.
• W4311698903 creator A5009906846 @default.
• W4311698903 creator A5016543619 @default.
• W4311698903 creator A5018530568 @default.
• W4311698903 creator A5025049545 @default.
• W4311698903 creator A5039371893 @default.
• W4311698903 creator A5044953606 @default.
• W4311698903 creator A5048924779 @default.
• W4311698903 creator A5050540189 @default.
• W4311698903 creator A5056379352 @default.
• W4311698903 creator A5076400034 @default.
• W4311698903 creator A5077188144 @default.
• W4311698903 creator A5080863932 @default.
• W4311698903 date "2022-11-01" @default.
• W4311698903 modified "2023-09-27" @default.
• W4311698903 title "P30 Real-world tolerability study of nintedanib in patients with progressive fibrosing interstitial lung disease compared to patients with idiopathic pulmonary fibrosis" @default.
• W4311698903 doi "https://doi.org/10.1136/thorax-2022-btsabstracts.166" @default.
• W4311698903 hasPublicationYear "2022" @default.
• W4311698903 type Work @default.
• W4311698903 citedByCount "0" @default.
• W4311698903 crossrefType "proceedings-article" @default.
• W4311698903 hasAuthorship W4311698903A5001206463 @default.
• W4311698903 hasAuthorship W4311698903A5008951890 @default.
• W4311698903 hasAuthorship W4311698903A5009906846 @default.
• W4311698903 hasAuthorship W4311698903A5016543619 @default.
• W4311698903 hasAuthorship W4311698903A5018530568 @default.
• W4311698903 hasAuthorship W4311698903A5025049545 @default.
• W4311698903 hasAuthorship W4311698903A5039371893 @default.
• W4311698903 hasAuthorship W4311698903A5044953606 @default.
• W4311698903 hasAuthorship W4311698903A5048924779 @default.
• W4311698903 hasAuthorship W4311698903A5050540189 @default.
• W4311698903 hasAuthorship W4311698903A5056379352 @default.
• W4311698903 hasAuthorship W4311698903A5076400034 @default.
• W4311698903 hasAuthorship W4311698903A5077188144 @default.
• W4311698903 hasAuthorship W4311698903A5080863932 @default.
• W4311698903 hasConcept C126322002 @default.
• W4311698903 hasConcept C167135981 @default.
• W4311698903 hasConcept C197934379 @default.
• W4311698903 hasConcept C2776715498 @default.
• W4311698903 hasConcept C2777543607 @default.
• W4311698903 hasConcept C2777714996 @default.
• W4311698903 hasConcept C2778341716 @default.
• W4311698903 hasConcept C2778375690 @default.
• W4311698903 hasConcept C2778715236 @default.
• W4311698903 hasConcept C2780171596 @default.
• W4311698903 hasConcept C2780252810 @default.
• W4311698903 hasConcept C71924100 @default.
• W4311698903 hasConcept C72563966 @default.
• W4311698903 hasConcept C90924648 @default.
• W4311698903 hasConceptScore W4311698903C126322002 @default.
• W4311698903 hasConceptScore W4311698903C167135981 @default.
• W4311698903 hasConceptScore W4311698903C197934379 @default.
• W4311698903 hasConceptScore W4311698903C2776715498 @default.
• W4311698903 hasConceptScore W4311698903C2777543607 @default.
• W4311698903 hasConceptScore W4311698903C2777714996 @default.
• W4311698903 hasConceptScore W4311698903C2778341716 @default.
• W4311698903 hasConceptScore W4311698903C2778375690 @default.
• W4311698903 hasConceptScore W4311698903C2778715236 @default.
• W4311698903 hasConceptScore W4311698903C2780171596 @default.
• W4311698903 hasConceptScore W4311698903C2780252810 @default.
• W4311698903 hasConceptScore W4311698903C71924100 @default.
• W4311698903 hasConceptScore W4311698903C72563966 @default.
• W4311698903 hasConceptScore W4311698903C90924648 @default.
• W4311698903 hasLocation W43116989031 @default.
• W4311698903 hasOpenAccess W4311698903 @default.
• W4311698903 hasPrimaryLocation W43116989031 @default.
• W4311698903 hasRelatedWork W2976928218 @default.
• W4311698903 hasRelatedWork W3022422513 @default.
• W4311698903 hasRelatedWork W3047341706 @default.
• W4311698903 hasRelatedWork W3136371725 @default.
• W4311698903 hasRelatedWork W3215070884 @default.
• W4311698903 hasRelatedWork W4223500234 @default.
• W4311698903 hasRelatedWork W4247250061 @default.
• W4311698903 hasRelatedWork W4311698903 @default.
• W4311698903 hasRelatedWork W4317838235 @default.
• W4311698903 hasRelatedWork W4367604041 @default.
• W4311698903 isParatext "false" @default.
• W4311698903 isRetracted "false" @default.
• W4311698903 workType "article" @default.